Pancreatic neuroendocrine tumors: Challenges in an underestimated disease

A. Viúdez, Ana De Jesus-Acosta, F. L. Carvalho, R. Vera, S. Martín-Algarra, N. Ramírez

Research output: Contribution to journalArticle


Pancreatic neuroendocrine tumours (PanNETs) are considered a relatively unusual oncologic entity. Due to its relative good prognosis, surgery remains the goal standard therapy not only in localized disease but also in the setting of locally or metastatic disease. Most of the patients are diagnosed in metastatic scenario, where multidisciplinary approach based on surgery, chemotherapies, liver-directed and/or molecular targeted therapies are commonly used. Owing to a deeper molecular knowledge of this disease, these targeted therapies are nowadays widely implemented, being the likely discovery of predictive biomarkers that would allow its use in other settings. This review is focused on describing the different classifications, etiology, prognostic biomarkers and multidisciplinary approaches that are typically used in PanNET.

Original languageEnglish (US)
Pages (from-to)193-206
Number of pages14
JournalCritical Reviews in Oncology/Hematology
StatePublished - May 1 2016



  • Foregut
  • Gastrointestinal neuroendocrine tumors
  • Pancreas surgery
  • Pancreatic Neuroendocrine Tumor (PanNET)
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this